Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05820568
Other study ID # 2022-02380-01-Pilot
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2, 2022
Est. completion date May 22, 2023

Study information

Verified date September 2023
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical is to pilot test an internet delivered cognitive behavior therapy (ICBT) based on intolerance of uncertainty (one of several existing specific cognitive models for how worry works) in treating generalised anxiety disorder (GAD). The main aims is to: - Test the preliminary effect of the intervention in lowering symptoms of GAD as measured by the self report scale GAD-7 - Test procedures for recruitment, assessment, treatment and follow up - Test the acceptability of the intervention as measured by the Client Satisfaction questionnaire-8, dropout and adverse events Participants will apply for treatment in an online system, be assessed via video by a licensed clinical psychologist and then receive a 10 week long ICBT intervention based on the intolerance of uncertainty model. This is a pilot study for an upcoming randomized controlled trial.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date May 22, 2023
Est. primary completion date May 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years old or more. - Diagnosis of GAD based on clinical assessment. - At least 10 points on GAD-7 at screening. - Proficient in written Swedish. - Access to internet enabled device and Swedish BankID for authentication - Able to make sufficient time for the 10 week long treatment - Consents to study Exclusion Criteria: - In need of treatment for other psychiatric diagnosis as priority (eg depression, psychosis) or high risk of suicide based on clinical assessment - Ongoing risk use of alcohol or drugs - Ongoing serious somatic of social disease/problem that is deemed to be to much of a hindrance for the completion of the treatment

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
ICBT-IU
Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry

Locations

Country Name City State
Sweden Internet Psychiatry Clinic, Psychiatry Southwest, SLSO, Region Stockholm Stockholm Huddinge

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Region Stockholm

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Rate of treatment dropout Patient terminates treatment ahead of schedule 10 weeks after treatment start
Other Adherence Number of modules completed 10 weeks after treatment start
Primary Generalized Anxiety Disorder 7-item (GAD7) Symptoms of generalized anxiety disorder measured by the self report measure GAD7. Scores range from 0-21 with higher scores indicating more generalized anxiety 10 weeks after treatment start
Secondary Treatment credibility A version of the credibility expectancy questionnaire used at the Internet Psychiatry Clinic in Sweden. Scores range from 5 to 50 with higher scores indicating more credibility. 2 weeks into treatment
Secondary Satisfaction with treatment Client Satisfaction Questionnaire 8 item version (CSQ8). Scores range from 8 to 32; scores of 8-13 indicate poor satisfaction, 14-19 fair satisfaction, 20-25 good satisfaction, and 26-32 excellent satisfaction. 10 weeks after treatment start
Secondary Symptoms of depression including suicidal ideation Measured with the Montgomery Åsberg Depression Rating Scale- Self report (MADRS-S). Scores range from 0-54 with higher scores indicating more depression 10 weeks after treatment start
Secondary Intolerance of uncertainty Measured with the Intolerance of Uncertainty Scale short version (IUS-12). Scores range from 12-60 with higher scores indicating more intolerance of uncertainty. 10 weeks after treatment start
Secondary Excessive worry Measured with the Penn State Worry Questionnaore (PSWQ). Scores range from 16-80 points with more points indicating more worry 10 weeks after treatment start
Secondary Symptoms of depression Measured with the Patient Health Questionnaire-9 item self report measure (PHQ9).The scale range is 0-27 with higher scores indication more depression. 10 weeks after treatment start
Secondary WHO Disability Assessment Schedule (WHODAS 2.0) self report (12 items) A health and disability metric developed by WHO. Scores range from 0-100% and represent the level of disability with 100% being complete disability to function in everyday life. 10 weeks after treatment start
See also
  Status Clinical Trial Phase
Terminated NCT03420456 - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Withdrawn NCT02382224 - Worry Exposure for Generalized Anxiety Disorder N/A
Completed NCT02306356 - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT01958788 - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder N/A
Completed NCT01681329 - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT01337713 - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD) N/A
Completed NCT01342120 - PHARMO Institute Seroquel Safety Study N/A
Completed NCT01971203 - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat N/A
Completed NCT00961298 - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Phase 4
Completed NCT01203293 - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector Phase 1
Completed NCT00744627 - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Phase 3
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00537615 - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers Phase 1
Completed NCT00515242 - Therapeutic Massage for Generalized Anxiety Disorder Phase 1/Phase 2
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00620776 - Combined Treatment for Generalized Anxiety Disorder (GAD) Phase 2